{"id":17951,"date":"2026-03-09T12:43:55","date_gmt":"2026-03-09T12:43:55","guid":{"rendered":"https:\/\/www.colorectalcancercanada.com\/?post_type=drug&#038;p=17951"},"modified":"2026-03-12T15:56:47","modified_gmt":"2026-03-12T15:56:47","slug":"regorafenib","status":"publish","type":"drug","link":"https:\/\/www.colorectalcancercanada.com\/fr\/drug\/regorafenib\/","title":{"rendered":"Regorafenib"},"content":{"rendered":"<p><strong>Indication<\/strong><\/p>\n<p>Le r\u00e9goraf\u00e9nib est indiqu\u00e9 chez les patients atteints d&rsquo;un CCRm qui ont d\u00e9j\u00e0 re\u00e7u les traitements suivants et dont la maladie a progress\u00e9 pendant ou apr\u00e8s ces traitements :<\/p>\n<ul>\n<li>Chimioth\u00e9rapie \u00e0 base de fluoropyrimidine<\/li>\n<li>Oxaliplatine<\/li>\n<li>Irinot\u00e9can<\/li>\n<li>Traitement anti-VEGF (facteur de croissance endoth\u00e9lial vasculaire) (p. ex. bevacizumab)<\/li>\n<li>Si leur cancer est de type sauvage <em>RAS<\/em>, un traitement anti-EGFR (r\u00e9cepteur du facteur de croissance \u00e9pidermique) (par exemple, le c\u00e9tuximab ou le panitumumab)<\/li>\n<\/ul>\n","protected":false},"template":"","crc_subtype":[401],"drug_stage":[402],"therapy_line":[],"health_canada_approval":[404],"cda_review":[405],"cda_recommendation":[406],"inesss_review":[407],"inesss_recommendation":[427],"pcpa_status":[425],"public_reimbursement":[],"class_list":["post-17951","drug","type-drug","status-publish","hentry","crc_subtype-none-fr","drug_stage-iv-fr","health_canada_approval-approved-fr","cda_review-completed-fr","cda_recommendation-positive-fr","inesss_review-termine-fr","inesss_recommendation-negative-fr-2","pcpa_status-non-poursuivi"],"_links":{"self":[{"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/drug\/17951","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/drug"}],"about":[{"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/types\/drug"}],"wp:attachment":[{"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/media?parent=17951"}],"wp:term":[{"taxonomy":"crc_subtype","embeddable":true,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/crc_subtype?post=17951"},{"taxonomy":"drug_stage","embeddable":true,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/drug_stage?post=17951"},{"taxonomy":"therapy_line","embeddable":true,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/therapy_line?post=17951"},{"taxonomy":"health_canada_approval","embeddable":true,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/health_canada_approval?post=17951"},{"taxonomy":"cda_review","embeddable":true,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/cda_review?post=17951"},{"taxonomy":"cda_recommendation","embeddable":true,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/cda_recommendation?post=17951"},{"taxonomy":"inesss_review","embeddable":true,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/inesss_review?post=17951"},{"taxonomy":"inesss_recommendation","embeddable":true,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/inesss_recommendation?post=17951"},{"taxonomy":"pcpa_status","embeddable":true,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/pcpa_status?post=17951"},{"taxonomy":"public_reimbursement","embeddable":true,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/public_reimbursement?post=17951"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}